Latest filing published 06 Jan 2021 for Alaunos Therapeutics, Inc., €234k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -46.0%Entry US$645.00 · Close at T+365 US$348.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Laurence James Neil Cooper: trading record in brief
This profile gathers the share dealings of Laurence James Neil Cooper in Alaunos Therapeutics, Inc. The record holds 21 filings, for trades running from 5 May 2015 to 4 January 2021.
On the open market, the record shows 1 purchase worth €26k and 2 sales worth €717k. The net balance comes to €691k on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 17 share grants and 1 option exercise. In 2021 alone, the filings show no purchases and 1 sale.
The record was last updated on 6 January 2021 with an open-market sale (€234k) in Alaunos Therapeutics, Inc. The clock since the last published purchase (9 November 2017) now reads 3,287 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Laurence James Neil Cooper
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 105,693 shares@ US$2.716.6% of flowCommon StockSEC:0001209191-21-002171:0
- 171,700 shares0Common StockSEC:0001209191-20-005780:0
- 44,642 shares@ US$2.248.8% of flowCommon StockSEC:0001209191-19-062290:0
- 110,694 shares@ US$4.8847.1% of flowCommon StockSEC:0001209191-19-062290:1
- 337,266 shares0Common StockSEC:0001209191-19-002778:0
- 446,428 shares0Common StockSEC:0001209191-19-002778:1
- 165,178 shares@ US$2.2420.0% of flowCommon StockSEC:0001209191-19-002778:2
- 42,920 shares@ US$1.663.8% of flowCommon StockSEC:0001209191-19-000586:0
- 26,178 shares@ US$1.662.3% of flowCommon StockSEC:0001209191-19-000586:1
- 16,156 shares@ US$1.871.6% of flowCommon StockSEC:0001209191-19-000586:2
- 123,333 shares@ US$4.4113.8% of flowCommon StockSEC:0001209191-18-033067:0
- 348,000 shares0Common StockSEC:0001209191-18-000993:0
- 26,178 shares@ US$4.142.8% of flowCommon StockSEC:0001209191-18-000993:1
- 16,157 shares@ US$4.141.7% of flowCommon StockSEC:0001209191-18-000993:2
- 6,440 shares@ US$4.680.8% of flowCommon StockSEC:0001209191-17-059988:0Canonical exit: 6 Feb 2018 (T+90)
- 132,000 shares@ US$7.1226.0% of flowCommon StockSEC:0001209191-17-031086:0
- 17,292 shares@ US$5.352.7% of flowCommon StockSEC:0001209191-17-000996:1
- 212,250 shares0Common StockSEC:0001209191-17-000996:0
- 116,667 shares@ US$6.8621.3% of flowCommon StockSEC:0001209191-16-118528:0
- 131,000 sharesCommon StockSEC:0001209191-16-088703:0
- 1,000,000 shares0Common StockSEC:0001209191-15-040045:0
21 of 21 declarations